Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

DarioHealth Q3 2026 Results: Net Loss of $8.85M, Loss Narrows

DarioHealth Corp. reported total revenues of $16.07 million for the nine months ended September 30, 2026, a decrease from $17.13 million in the prior year period. The company significantly reduced its net loss to $25.02 million compared to $32.68 million in 2025, driven by lower operating expenses across R&D, sales, and administrative functions.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue5.35.0
Gross profit3.13.0
Profit before tax-8.9-10.5
Net income-8.8-10.5
EPS (diluted, $ a share)$0.73$2.96

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+6.1%
Gross margin59.2%
Operating margin-151.5%
Source

10-Q filed with the SEC, NASDAQ: DRIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

DarioHealth Corp.: key numbers

Share price
$1.15Close, Nov 17
Market cap
$13M
Shares outstanding
11.29MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from DarioHealth Corp.

All →
4:07 PM ET 8-K
Leadership Change

DarioHealth Leadership Change

DarioHealth Corp. appointed John R. Palumbo as Chairman of the Board, effective November 3, 2026. He succeeds Yoav Shaked, who will remain on the Board as a director.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.